Abstract: The invention relates to molecular biology, biotechnology, medicine, veterinary science. A group of inventions is proposed: a fusion protein comprising a ligand to MATN1 protein, and a growth factor of EGF, TGF, FGF, IGF, connected via a flexible link; such fusion protein further comprising the Fc-fragment of an antibody or a polypeptide binding with FcRn and/or transferrin or a fragment thereof, connected via a flexible link; encoding polynucleotide, a genetic construct for the synthesis of the fusion protein in producer cells, or cells of a target organism, the fusion protein producer, a producer of the genetic construct, a preparation for the regeneration of cartilage containing at least 1 fusion protein or genetic construct, for parenteral or, in the case of the preparation based on at least 1 fusion protein containing the transport domain, —oral administration, in the latter case the preparation is enclosed in an enteric coating.
Type:
Grant
Filed:
July 13, 2017
Date of Patent:
April 12, 2022
Assignee:
LIMITED LIABILITY COMPANY BIOCHEMICAL AGENT
Abstract: The present disclosure describes the C-type lectin CLEC11a as a bone growth factor. Clec11a-deficient mice showed reduced bone volume and mineralization, while bone resorption remained unchanged. Administration of recombinant Clec11a systemically promoted bone formation in mice at risk for osteoporosis.
Type:
Grant
Filed:
April 18, 2016
Date of Patent:
March 29, 2022
Assignee:
The Board of Regents of The University of Texas System
Abstract: A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to Ror2 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to Ror2 protein. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.
Type:
Grant
Filed:
May 12, 2017
Date of Patent:
February 22, 2022
Assignee:
BioAtla, Inc.
Inventors:
Jay M. Short, Hwai Wen Chang, Gerhard Frey
Abstract: Provided is an agent for preventing and/or treating osteogenesis imperfecta, osteoporosis and/or osteoarthritis, the agent comprising a peptide consisting of one of the following amino acid sequences: (a) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu (SEQ ID NO: 1) and (b) Val-Asn-Pro-Glu (SEQ ID NO: 2). The agent of the present invention can be orally ingested, has osteogenic function, and has a preventive and/or healing-promoting effect on bone fractures and is therefore very useful for prevention and/or treatment of osteogenesis imperfecta, osteoporosis and/or osteoarthritis.
Type:
Grant
Filed:
June 27, 2017
Date of Patent:
February 8, 2022
Assignee:
Pharma Foods International Co., Ltd.
Inventors:
Chihiro Suzuki, Utano Nakamura, Mujo Kim
Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
Type:
Grant
Filed:
July 27, 2017
Date of Patent:
February 1, 2022
Assignee:
Genentech, Inc.
Inventors:
Michael Townsend, Alvernia Francesca Setiadi, Tracy Staton
Abstract: The present invention is directed towards the use of Growth Differentiation Factor 1 (Gdf1) and variants thereof to modulate and regulate ceramide neutralization in cells.
Abstract: Provided herein are, inter alia, compositions and methods for identifying and using agents capable of inhibiting myofibroblast transition as well as methods for treating diseases associated with the same in a subject in need thereof.
Abstract: The disclosure relates to the use of variants of C-type natriuretic peptide (CNP) to treat osteoarthritis, to ameliorate one or more symptoms of osteoarthritis, and to treat disorders having an osteoarthritis component.
Type:
Grant
Filed:
December 8, 2016
Date of Patent:
December 21, 2021
Assignee:
BIOMARIN PHARMACEUTICAL INC.
Inventors:
Charles A. O'Neill, Todd M. Oppeneer, Jason K. Pinkstaff
Abstract: The invention regards the modulation of TGF-? activity by administering to a subject an antibody that binds to TGF-?, thereby increasing bone growth, bone formation, bone mass and bone strength. The antibody acts to increase osteoblast number and function while at the same time decreasing osteoclast number and function. Such drugs are useful in the treatment of diseases or disorders such as osteoporosis, Paget's disease, metastatic bone cancer, myeloma bone disease, bone fractures, etc.
Abstract: The present invention provides new protease-resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.
Abstract: There is disclosed herein compositions, methods, uses and systems for reducing pain in a patient that emanates from a body area, preferably spine or joint. Methods of treatment or prevention are described for a disease or condition selected from degenerative disc disease, disc injury, pain, arthritis, or suspected arthritis.
Abstract: There is disclosed herein compositions, methods, uses and systems for reducing pain in a patient that emanates from a body area, preferably spine or joint. Methods of treatment or prevention are described for a disease or condition selected from degenerative disc disease, disc injury, pain, arthritis, or suspected arthritis.
Abstract: Disclosed are compositions and methods for modulating the activity of TGF-?. More particularly, compositions and methods for modulating the release of active TGF-? from an LRRC33-TGF-? prodomain-TGF-? ternary complex are provided, as are and methods of treatment based upon such modulation.
Type:
Grant
Filed:
October 25, 2017
Date of Patent:
October 5, 2021
Assignee:
THE CHILDREN'S MEDICAL CENTER CORPORATION
Inventors:
Timothy Alan Springer, Chafen Lu, Yan Qin, Aiping Jiang
Abstract: In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in a subject in need thereof. Subjects in need include, for example, subjects having anemia and/or ineffective erythropoiesis as a result of having reduced GATA-1, heat shock factor and/or NFE2 levels as compared to the levels in a reference population.
Type:
Grant
Filed:
November 4, 2016
Date of Patent:
September 21, 2021
Assignee:
ACCELERON PHARMA INC.
Inventors:
Ravindra Kumar, Pedro Martinez, Naga Venkata Sai Rajasekhar Suragani
Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
Type:
Grant
Filed:
November 21, 2018
Date of Patent:
September 7, 2021
Assignee:
ROCHE GLYCART AG
Inventors:
Oliver Ast, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or binds to the cartilage of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of a drug to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.
Type:
Grant
Filed:
September 9, 2016
Date of Patent:
August 17, 2021
Assignees:
FRED HUTCHINSON CANCER RESEARCH CENTER, BLAZE BIOSCIENCE, INC.
Inventors:
James Olson, Andrew David Strand, Emily June Girard, Roland Strong, Christopher Mehlin, Colin Correnti, Natalie Nairn
Abstract: A composition comprising a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analogue is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.
Abstract: The present invention relates to compositions and methods useful for treating structures of the vertebral column, including vertebral bodies. In one embodiment, a method for promoting bone formation in a vertebral body comprising providing a composition comprising a PDGF solution and a biocompatible matrix and applying the composition to at least one vertebral body. Promoting bone formation in a vertebral body, according to some embodiments, can increase bone volume, mass, and/or density leading to an increase in mechanical strength of the vertebral body treated with a composition of the present invention.
Type:
Grant
Filed:
September 14, 2015
Date of Patent:
July 13, 2021
Assignee:
BioMimetic Therapeutics, LLC
Inventors:
Charles E. Hart, Samuel E. Lynch, Conan S. Young, Dan Perrien
Abstract: Antibodies that neutralize Notum Pectinacetylesterase are described, as well as compositions comprising them, and methods of their use to treat diseases and disorders affecting the bone.
Type:
Grant
Filed:
February 15, 2019
Date of Patent:
July 13, 2021
Assignee:
Lexicon Pharmaceuticals, Inc.
Inventors:
Robert Joseph Brommage, Jr., Xiao Feng, Seokjoo Hong, Gregory Landes, Jeff Liu, David George Potter, David Reed Powell
Abstract: Provided in the present invention are a Slit2D2-HAS fusion protein and the use thereof against tumours. The fusion protein can significantly inhibit the migration of tumour cells. Also provided in the present invention are a pharmaceutical composition comprising the fusion protein and a method for preparing the fusion protein.